- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Bank of America Raises Johnson & Johnson Price Target
Analysts Boost Outlook for Pharmaceutical Giant
Apr. 16, 2026 at 1:38pm
Got story updates? Submit your updates here. ›
The specialized industrial equipment that powers Johnson & Johnson's pharmaceutical production highlights the company's technological sophistication and manufacturing prowess.New Brunswick TodayBank of America has increased its price target for Johnson & Johnson (NYSE:JNJ) from $253.00 to $254.00 and maintained a 'neutral' rating on the stock. The new target suggests a potential upside of 7.38% from the company's current share price.
Why it matters
Johnson & Johnson is a major pharmaceutical and consumer healthcare company, so changes to its stock price target by influential analysts can impact investor sentiment and the broader market's view of the company's performance and prospects.
The details
In a research report released on Wednesday, Bank of America's equity analysts raised their price target for Johnson & Johnson, citing the company's ongoing business operations and product pipeline. The new $254.00 target price represents a modest increase from the previous $253.00 target, and the analysts maintained their 'neutral' rating on the stock.
- Bank of America issued the updated price target and rating on April 16, 2026.
The players
Bank of America
A major U.S. multinational investment bank and financial services company.
Johnson & Johnson
A global healthcare company that develops pharmaceutical, medical device, and consumer packaged goods products.
What’s next
Investors will be watching to see if Johnson & Johnson's stock price responds to the updated price target from Bank of America in the coming days and weeks.
The takeaway
While the price target increase from Bank of America is modest, it reflects the continued confidence in Johnson & Johnson's business fundamentals and product pipeline among Wall Street analysts covering the healthcare giant.
